On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 29, 2023 4:01 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases FY 2023 Report, Shares Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the financial results for its fiscal year 2023, the period ending June 30, 2023. In addition, the company provided a status update on its pharmaceutical drug-development programs as well as the commercial segment for BayMedica LLC, its wholly owned subsidiary. Highlights of the report include total sales for subsidiary BayMedica of rare cannabinoids in the health and wellness sector reaching $4.1 million, an increase of 280% over the previous fiscal year and $2.3 million in revenue for…

Continue Reading

FridaySep 29, 2023 1:59 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company would focus on accelerating precision and personalized medicine for longevity powered by mutually reinforcing artificial intelligence (“AI”) and biotechnology platforms to enable early diagnosis, better targeted treatments and drug discovery. GEDi Cube is an artificial intelligence medical technology company. According…

Continue Reading

FridaySep 29, 2023 1:39 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Upcoming $1.6M Registered Direct Offering

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a securities purchase agreement with a single healthcare-focused institutional investor; the agreement is for the purchase of 1,618,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. According to the announcement, Lexaria also agreed to issue and sell warrants to purchase up to 1,618,330 shares of common stock to the same investor. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.97. The warrants will become exercisable six…

Continue Reading

FridaySep 29, 2023 1:06 pm

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Announced Two Additional K5 ASR Orders Added to Expansion Contract

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is continuing to add to its client roster. This time the company has inked deals with its first-ever ASR clients in Louisiana: two casinos, one located in Shreveport and the other in Bossier City. According to the announcement, the two K5 ASR contracts have been executed as part of a larger agreement Knightscope received earlier this month. The contracts call for the two casinos to each receive a K5 robot. These two new ASRs bring the total robots under the contract to five, with…

Continue Reading

FridaySep 29, 2023 11:33 am

QualityStocksNewsBreaks — LNG Energy Group Corp. (TSX.V: LNGE) (TSX.V: LNGE.WT) (OTCQB: LNGNF) (FRA: 6MH) Files Mind Cure Financial Docs; Announces Options and DSU Grants

LNG Energy Group (TSX.V: LNGE) (TSX.V: LNGE.WT) (OTCQB: LNGNF) (FRA: 6MH), a company focused on the acquisition and development of natural-gas production and exploration assets in Latin America, has filed the consolidated annual financial statements and management discussion and analysis for Mind Cure Health Inc., its predecessor entity; the financial statements were filed for the fiscal year ended May 31, 2023. As part of the announcement, the company also noted that CFO Angel Roa and COO Nicolas Ziperovich have agreed to settle management and consulting fees owed to them in common capital shares of the company. Specifically, Roa will receive 269,280 common…

Continue Reading

FridaySep 29, 2023 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video:  Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program With NDA approval, we anticipate the potential to…

Continue Reading

FridaySep 29, 2023 10:30 am

GEMXX Corp. (GEMZ) Plans 300% YoY Expansion in Gemstone and Jewelry Production to Meet Growing Demand

GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand Its shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months Although officially recognized…

Continue Reading

FridaySep 29, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral…

Continue Reading

FridaySep 29, 2023 9:00 am

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

by Elaine Mendonça On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8. The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites. To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function,…

Continue Reading

ThursdaySep 28, 2023 1:08 pm

QualityStocksNewsBreaks – Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Completes First Phase of Drilling Initiatives Across PCH Iconic Clay Project

Appia (CSE: API) (OTCQX: APAAF) (FSE: A0I0, A0I0.F, A0I0.MU, A0I0.BE) today provided an update on the progress of its ongoing drilling program to outline the extent of the mineralized zone at Target IV on its PCH Iconic Clay Project in Brazil. The company has processed and sent 2,255 samples for analysis, from both the Reverse Circulation (“RC”) and Auger drill programs to date and expects to release results in the near future. “Appia’s RC extensive drilling program at Target IV has reached a total of 147 holes, and we have now completed the first phase of the multi-phase drilling initiatives…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered